What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.Digestive diseases and sciences · 2002
   Pooled it
2. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.Gut · 2009
   Trial
3. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.Gut · 2005
   Trial
4. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.Gut · 2004
   Trial
5. No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.International journal of colorectal disease · 2003
   Trial
6. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.Gut · 2001
   Trial
7. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.Gut · 1999
   Trial
8. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.European journal of clinical pharmacology · 2014
   Article
9. Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.Drug design, development and therapy · 2011
   Review
10. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.The Journal of experimental medicine · 2005
    Article
11. Advances in colonic drug delivery.Drugs · 2005
    Review
12. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.Gut · 2000
    Article
13. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.Drugs · 1999
    Review
14. [Consequences of galenic considerations and clinical results for therapy of ulcerative colitis].Medizinische Klinik (Munich, Germany : 1983) · 1999
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as